Back to search

Article

Cross-Species Hepatic Metabolism of the Antileishmanial Chalcone NAT22 Generates Metabolites with Enhanced Affinity for the Parasite Target cTXNPx

2026-03-03

Abstract excerpt

<h4>Background: </h4> /Objectives: Human and canine leishmaniasis are neglected diseases with limited therapeutic options. The nitrochalcone NAT22, a high-affinity inhibitor of the essential parasite enzyme tryparedoxin peroxidase (cTXNPx), has emerged as a promising antileishmanial candidate. Interestingly, NAT22 demonstrated superior efficacy when administered orally rather than intralesionally, suggesting metab...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
dd1856ef-df73-5aa0-9852-4a653639efec
DOI
10.20944/preprints202603.0166.v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Cross-Species Hepatic Metabolism of the Antileishmanial Chalcone NAT22 Generates Metabolites with Enhanced Affinity for the Parasite Target cTXNPxDOI 10.20944/preprints202603.0166.v1
Select a neighboring publication to make it the new centre.